Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cellular Oncology

01.08.2016 | Report

Inactivation of the LKB1-AMPK signaling pathway does not contribute to salivary gland tumor development - a short report

verfasst von: Natascha Cidlinsky, Giada Dogliotti, Tobias Pukrop, Rudolf Jung, Florian Weber, Michael P. Krahn

Erschienen in: Cellular Oncology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Activation of AMPK by the tumor suppressor LKB1 represents an essential gatekeeping step for cells under energetic stress to prevent their growth and proliferation by inhibiting mTOR activation, until the energy supply normalizes. The LKB1/AMPK pathway is frequently downregulated in various types of cancer, thereby uncoupling tumor cell growth and proliferation from energy supply. As yet, little information is available on the role of the LKB1/AMPK pathway in tumors derived from salivary gland tissues.

Methods

We performed LKB1 protein expression and AMPK and mTOR activation analyses in several salivary gland tumor types and their respective healthy control tissues using immunohistochemistry.

Results

No significant downregulation of LKB1 expression or decreased activation of AMPK or mTOR were observed in any of the salivary gland tumors tested. In contrast, we found that the salivary gland tumors exhibited an increased rather than a decreased AMPK activation. Although the PI3K/Akt pathway was found to be activated in most of the analyzed tumor samples, the unchanged robust activity of LKB1/AMPK likely prevents (over)activation of mTOR.

Conclusion

In contrast to many other types of cancer, inactivation or downregulation of the LKB1/AMPK pathway does not substantially contribute to the pathogenesis of salivary gland tumors.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
J. Spicer, S. Rayter, N. Young, R. Elliott, A. Ashworth, D. Smith, Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1. Oncogene 22, 4752–4756 (2003)CrossRefPubMed
2.
D. P. Smith, S. I. Rayter, C. Niederlander, J. Spicer, C. M. Jones, A. Ashworth, LIP1, A cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1. Hum. Mol. Genet. 10, 2869–2877 (2001)CrossRefPubMed
3.
O. Ossipova, N. Bardeesy, R. A. DePinho, J. B. Green, LKB1 (XEEK1) regulates Wnt signalling in vertebrate development. Nat. Cell Biol. 5, 889–894 (2003)CrossRefPubMed
4.
D. A. Guertin, D. M. Sabatini, Defining the role of mTOR in cancer. Cancer Cell 12, 9–22 (2007)CrossRefPubMed
5.
C. Boehlke, F. Kotsis, V. Patel, S. Braeg, H. Voelker, S. Bredt, T. Beyer, H. Janusch, C. Hamann, M. Godel, K. Muller, M. Herbst, M. Hornung, M. Doerken, M. Kottgen, R. Nitschke, P. Igarashi, G. Walz, E. W. Kuehn, Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat. Cell Biol. 12, 1115–1122 (2010)CrossRefPubMedPubMedCentral
6.
H. Mehenni, N. Lin-Marq, K. Buchet-Poyau, A. Reymond, M. A. Collart, D. Picard, S. E. Antonarakis, LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes. Hum. Mol. Genet. 14, 2209–2219 (2005)CrossRefPubMed
7.
P. Y. Zeng, S. L. Berger, LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. Cancer Res. 66, 10701–10708 (2006)CrossRefPubMed
8.
K. Goetze, C. G. Fabian, A. Siebers, L. Binz, D. Faber, S. Indraccolo, G. Nardo, U. G. Sattler, W. Mueller-Klieser, Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system. Cell. Oncol. 38, 377–385 (2015)CrossRef
9.
H. R. Oh, C. H. An, N. J. Yoo, S. H. Lee, Somatic mutations of amino acid metabolism-related genes in gastric and colorectal cancers and their regional heterogeneity--a short report. Cell. Oncol. 37, 455–461 (2014)CrossRef
10.
M. Cargnello, J. Tcherkezian, P. P. Roux, The expanding role of mTOR in cancer cell growth and proliferation. Mutagenesis 30, 169–176 (2015)CrossRefPubMed
11.
K. Inoki, T. Zhu, K. L. Guan, TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577–590 (2003)CrossRefPubMed
12.
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., and Cantley, L. C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 6, 91–99 (2004)
13.
D. M. Gwinn, D. B. Shackelford, D. F. Egan, M. M. Mihaylova, A. Mery, D. S. Vasquez, B. E. Turk, R. J. Shaw, AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214–226 (2008)CrossRefPubMedPubMedCentral
14.
A. M. Arsham, J. J. Howell, M. C. Simon, A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem. 278, 29655–29660 (2003)CrossRefPubMed
15.
N. Kimura, C. Tokunaga, S. Dalal, C. Richardson, K. Yoshino, K. Hara, B. E. Kemp, L. A. Witters, O. Mimura, K. Yonezawa, A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells. 8, 65–79 (2003)
16.
D. B. Shackelford, D. S. Vasquez, J. Corbeil, S. Wu, M. Leblanc, C. L. Wu, D. R. Vera, R. J. Shaw, mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. U. S. A. 106, 11137–11142 (2009)CrossRefPubMedPubMedCentral
17.
Corradetti, M. N., Inoki, K., Bardeesy, N., DePinho, R. A., and Guan, K. L. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 18, 1533–1538 (2004)
18.
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., Depinho, R. A., Montminy, M., and Cantley, L. C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 310, 1642–1646 (2005)
19.
B. Faubert, E. E. Vincent, M. C. Poffenberger, R. G. Jones, The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer Lett. 356, 165–170 (2015)CrossRefPubMed
20.
A. Hemminki, D. Markie, I. Tomlinson, E. Avizienyte, S. Roth, A. Loukola, G. Bignell, W. Warren, M. Aminoff, P. Hoglund, H. Jarvinen, P. Kristo, K. Pelin, M. Ridanpaa, R. Salovaara, T. Toro, W. Bodmer, S. Olschwang, A. S. Olsen, M. R. Stratton, A. de la Chapelle, L. A. Aaltonen, A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391, 184–187 (1998)CrossRefPubMed
21.
D. E. Jenne, H. Reimann, J. Nezu, W. Friedel, S. Loff, R. Jeschke, O. Muller, W. Back, M. Zimmer, Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 18, 38–43 (1998)CrossRefPubMed
22.
H. Jeghers, K. V. Mc, K. H. Katz, Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits. a syndrome of diagnostic significance. N. Engl. J. Med. 241, 1031–1036 (1949)CrossRefPubMed
23.
F. M. Giardiello, J. D. Brensinger, A. C. Tersmette, S. N. Goodman, G. M. Petersen, S. V. Booker, M. Cruz-Correa, J. A. Offerhaus, Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119, 1447–1453 (2000)CrossRefPubMed
24.
M. Sanchez-Cespedes, A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 26, 7825–7832 (2007)CrossRefPubMed
25.
K. Vaahtomeri, T. P. Makela, Molecular mechanisms of tumor suppression by LKB1. FEBS Lett. 585, 944–951 (2011)CrossRefPubMed
26.
B. Gao, Y. Sun, J. Zhang, Y. Ren, R. Fang, X. Han, L. Shen, X. Y. Liu, W. Pao, H. Chen, H. Ji, Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. J Thorac Oncol. 5, 1130–1135 (2010)
27.
H. Ji, M. R. Ramsey, D. N. Hayes, C. Fan, K. McNamara, P. Kozlowski, C. Torrice, M. C. Wu, T. Shimamura, S. A. Perera, M. C. Liang, D. Cai, G. N. Naumov, L. Bao, C. M. Contreras, D. Li, L. Chen, J. Krishnamurthy, J. Koivunen, L. R. Chirieac, R. F. Padera, R. T. Bronson, N. I. Lindeman, D. C. Christiani, X. Lin, G. I. Shapiro, P. A. Janne, B. E. Johnson, M. Meyerson, D. J. Kwiatkowski, D. H. Castrillon, N. Bardeesy, N. E. Sharpless, K. K. Wong, LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807–810 (2007)CrossRefPubMed
28.
J. P. Koivunen, J. Kim, J. Lee, A. M. Rogers, J. O. Park, X. Zhao, K. Naoki, I. Okamoto, K. Nakagawa, B. Y. Yeap, M. Meyerson, K. K. Wong, W. G. Richards, D. J. Sugarbaker, B. E. Johnson, P. A. Janne, Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br. J. Cancer 99, 245–252 (2008)CrossRefPubMedPubMedCentral
29.
M. Sanchez-Cespedes, P. Parrella, M. Esteller, S. Nomoto, B. Trink, J. M. Engles, W. H. Westra, J. G. Herman, D. Sidransky, Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62, 3659–3662 (2002)PubMed
30.
S. N. Wingo, T. D. Gallardo, E. A. Akbay, M. C. Liang, C. M. Contreras, T. Boren, T. Shimamura, D. S. Miller, N. E. Sharpless, N. Bardeesy, D. J. Kwiatkowski, J. O. Schorge, K. K. Wong, D. H. Castrillon, Somatic LKB1 mutations promote cervical cancer progression. PLoS One 4, e5137 (2009)CrossRefPubMedPubMedCentral
31.
C. M. Contreras, S. Gurumurthy, J. M. Haynie, L. J. Shirley, E. A. Akbay, S. N. Wingo, J. O. Schorge, R. R. Broaddus, K. K. Wong, N. Bardeesy, D. H. Castrillon, Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res. 68, 759–766 (2008)CrossRefPubMed
32.
A. Rowan, M. Churchman, R. Jefferey, A. Hanby, R. Poulsom, I. Tomlinson, In situ analysis of LKB1/STK11 mRNA expression in human normal tissues and tumours. J. Pathol. 192, 203–206 (2000)CrossRefPubMed
33.
I. P. Ribeiro, F. Marques, F. Caramelo, J. Pereira, M. Patricio, H. Prazeres, J. Ferrao, M. J. Juliao, M. Castelo-Branco, J. B. de Melo, I. P. Baptista, I. M. Carreira, Genetic gains and losses in oral squamous cell carcinoma: impact on clinical management. Cell. Oncol. 37, 29–39 (2014)CrossRef
34.
T. Nakaoka, A. Ota, T. Ono, S. Karnan, H. Konishi, A. Furuhashi, Y. Ohmura, Y. Yamada, Y. Hosokawa, Y. Kazaoka, Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell. Oncol. 37, 119–129 (2014)CrossRef
35.
C. Salazar, R. Nagadia, P. Pandit, J. Cooper-White, N. Banerjee, N. Dimitrova, W. B. Coman, C. Punyadeera, A novel saliva-based microRNA biomarker panel to detect head and neck cancers. Cell. Oncol. 37, 331–338 (2014)CrossRef
36.
L. Thompson, World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J. 85, 74 (2006)PubMed
37.
S. Kato, S. K. Elkin, M. Schwaederle, B. N. Tomson, T. Helsten, J. L. Carter, R. Kurzrock, Genomic landscape of salivary gland tumors. Oncotarget 28, 25631–25645 (2015)CrossRef
38.
T. Ettl, S. Schwarz-Furlan, F. Haubner, S. Muller, J. Zenk, M. Gosau, T. E. Reichert, K. Zeitler, The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol. 48, 822–830 (2012)CrossRefPubMed
39.
N. M. Ghahhari, H. M. Ghahhari, M. Kadivar, Could a possible crosstalk between AMPK and TGF-beta signaling pathways be a key player in benign and malignant salivary gland tumors? Onkologie 35, 770–774 (2012)CrossRefPubMed
40.
A. Sen, Z. Nagy-Zsver-Vadas, M. P. Krahn, Drosophila PATJ supports adherens junction stability by modulating Myosin light chain activity. J. Cell Biol. 199, 685–698 (2012)CrossRefPubMedPubMedCentral
41.
J. Boudeau, A. Kieloch, D. R. Alessi, A. Stella, G. Guanti, N. Resta, Functional analysis of LKB1/STK11 mutants and two aberrant isoforms found in Peutz-Jeghers syndrome patients. Hum. Mutat. 21, 172 (2003)CrossRefPubMed
42.
C. Forcet, S. Etienne-Manneville, H. Gaude, L. Fournier, S. Debilly, M. Salmi, A. Baas, S. Olschwang, H. Clevers, M. Billaud, Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. Hum. Mol. Genet. 14, 1283–1292 (2005)CrossRefPubMed
43.
A. F. Baas, J. Boudeau, G. P. Sapkota, L. Smit, R. Medema, N. A. Morrice, D. R. Alessi, H. C. Clevers, Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J. 22, 3062–3072 (2003)CrossRefPubMedPubMedCentral
44.
J. Boudeau, A. F. Baas, M. Deak, N. A. Morrice, A. Kieloch, M. Schutkowski, A. R. Prescott, H. C. Clevers, D. R. Alessi, MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J. 22, 5102–5114 (2003)CrossRefPubMedPubMedCentral
45.
Dorfman, J., and Macara, I. G. STRADalpha regulates LKB1 localization by blocking access to importin-alpha, and by association with Crm1 and exportin-7. Mol Biol Cell. 19, 1614–1626 (2008)
46.
Y. Nakada, T. G. Stewart, C. G. Pena, S. Zhang, N. Zhao, N. Bardeesy, N. E. Sharpless, K. K. Wong, D. N. Hayes, D. H. Castrillon, The LKB1 tumor suppressor as a biomarker in mouse and human tissues. PLoS One 8, e73449 (2013)CrossRefPubMedPubMedCentral
47.
48.
Metadaten
Titel
Inactivation of the LKB1-AMPK signaling pathway does not contribute to salivary gland tumor development - a short report
verfasst von
Natascha Cidlinsky
Giada Dogliotti
Tobias Pukrop
Rudolf Jung
Florian Weber
Michael P. Krahn
Publikationsdatum
01.08.2016
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 4/2016
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-016-0290-8

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Open Access 22.02.2024 | Pathologie | Originalien

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

21.02.2024 | Thrombozytopenie | CME

Knochenmarkhistologie bei Zytopenien
Beitrag zur hämatologischen Differenzialdiagnostik

Open Access 21.02.2024 | Fettleber | Originalien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien
Automatische Quantifizierung von Leberverfettung